TEVA PHARMACEUTICAL INDUSTRIES LTD - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Teva Pharmaceutical Industries Ltd. on August 31, 2026. The report details a material modification to the rights of security holders regarding the company's American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and securities structure changes rather than financial performance.
Material Changes
- ADS Program Termination: The Company executed Amendment No. 1 to its Deposit Agreement to terminate its ADS program.
- Mandatory Exchange: A mechanism was established for the mandatory exchange of ADSs for ordinary shares. Each ADS will be exchanged for one ordinary share (par value NIS 0.10).
- Direct Listing: The Company intends to list its ordinary shares directly on the New York Stock Exchange (NYSE).
- Effective Date: The termination of the ADS Program is expected to occur at the open of business on September 14, 2026. From this date, all outstanding ADSs will be cancelled.
Outlook and Management Commentary
Management previously disclosed the intent to list ordinary shares on the NYSE in the Quarterly Report on Form 10-Q filed on July 29, 2026. This 8-K formalizes the amendment required to facilitate the transition from the ADS structure to direct listing of ordinary shares. No specific financial guidance or risk factors regarding operations were disclosed in this specific filing.
Investor Verification Checklist
- Confirm the exact timing of the ADS cancellation and the availability of ordinary shares for trading on September 14, 2026.
- Verify the conversion ratio (1 ADS to 1 Ordinary Share) and ensure brokerage accounts are updated accordingly.
- Review the full text of Amendment No. 1 (Exhibit 4.1) for any specific conditions or exceptions to the mandatory exchange.
- Check for subsequent filings regarding the official commencement of trading for the ordinary shares on the NYSE.